Cardiology

May 2026 saw substantial FDA decisions, major trial results, guideline updates, and more.

Phase 3 post hoc data linked lorundrostat to lower systolic blood pressure and albuminuria in patients with hypertension and CKD.

FDA accepted a priority review sNDA for mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

FDA De Novo classification clears Cardiosense PCWP Analysis Software to estimate filling pressures in selected adults with HFrEF.

Lilly reports dose-dependent PCSK9 and LDL-C reductions with single-dose VERVE-102 in interim phase 1b hypercholesterolemia data.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Wilcox discusses the recent HFSA statement aiming to identify the unique characteristics of HFmrEF and define an alternative treatment pathway.

Deepak Bhatt, MD, MPH, MBA, discusses his recent presentation at the ASPC 2026 Virtual Imaging Symposium and how plaque imaging can change the MI landscape.

FDA granted priority review to asundexian for secondary prevention after non-cardioembolic ischemic stroke or TIA.

FDA approved baxdrostat as add-on therapy for adults with hypertension not controlled on other medications.

Stay updated with the latest healthcare breakthroughs, including FDA submissions and new cardiology guidelines.

Barry Borlaug, MD, discusses his recent publication collecting existing evidence on HFmrEF to reflect current data regarding treatment and management.

Marc Ruel, MD, MPH, discusses the progress made since in the 11 years since the last guidelines, both in treatment and therapy.

Payam Dehghani, MD, discusses his sub-study of the NACMI registry, following patients with COVID-19 and STEMI who survived to hospital discharge.

Pugazhendhi Vijayaraman, MD, discusses his recent presentation of the final results of LEADR LBBAP, simplifying the lead placement problems faced by earlier models.

Lucas Boersma, MD, PhD, discusses the 1-year results of the Enlighten study, highlighting effective defibrillation, low rate of complications, and high ATP success.

Mehdi Shishehbor, DO, PhD, discusses the 6-month results from his recent study, confirming the efficacy of the LimFlow System in patients with CLTI.

Erin Ferranti, PhD, MPH, discusses the new guidelines and their implications for continued enhancement of both access to and outcomes of postpartum care.

Sameh Sayfo, MD, discusses his recent analysis of the DETOUR2 study, highlighting the efficacy of the DETOUR system for patients regardless of runoff.

Bilchick discusses his recent study, highlighting a reduced risk of atrial fibrillation in patients taking prescription GLP-1 RAs irrespective of weight loss.

Saseen discusses the current dyslipidemia treatment landscape, highlighting current challenges and potential paths forward.

Stay updated with the latest healthcare breakthroughs, including data from DDW and a new podcast episode.

Ahmad Masri, MD, from OHSU, discusses the positive topline results from this phase 3 trial, highlighting a new path forward for nHCM.

Patient education may be the missing piece needed to bridge the gap between hypertension treatments and improved outcomes.